Establish Your Innovation Hub at RESI JPM 2027

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

Every January, JPM Healthcare Week transforms San Francisco into the global center of the life science industry, bringing together investors, pharmaceutical executives, biotech leaders, and innovators from around the world. For organizations looking to showcase their regional ecosystem, portfolio companies, or innovation network, RESI JPM 2027 offers a unique opportunity to establish a visible and strategic presence during one of the industry’s most influential weeks.

Located within the San Francisco Marriott Marquis, RESI JPM is the premier partnering conference dedicated to early-stage life science companies. The event connects startups with active investors, strategic partners, and business development professionals through curated partnering meetings, educational programming, and networking opportunities.

Life Science Nation invites regional organizations, innovation hubs, accelerators, and industry partners to create their own branded Innovation Hub alongside RESI JPM. These flexible hosting opportunities allow organizations to provide a central gathering place for their ecosystem while taking advantage of the high concentration of attendees already participating in RESI and JPM Healthcare Week.

RESI JPM 2027 Venue: Salons 9–15 (Yerba Buena Ballroom, Lower B2 Level) with total space exceeding 17,000 sq ft.

Organizations can kick off the week with a private networking reception on Sunday, welcoming investors, founders, corporate partners, and key stakeholders before the week’s meetings begin. During RESI JPM on Monday and Tuesday, dedicated salon spaces adjacent to the conference offer an ideal location for hosting meetings, showcasing portfolio companies, conducting presentations, and serving as a home base for delegates throughout the event.

Tech/Innovation hubs also benefit from prominent branding within the RESI environment and the opportunity for their startup cohorts to engage directly in RESI’s partnering platform, creating additional exposure and meeting opportunities with investors and strategic partners.

Whether representing a regional life science cluster, government agency, incubator, accelerator, or investment organization, establishing an Innovation Hub at RESI JPM positions your organization at the center of the world’s largest life science partnering week while providing lasting value for your innovation ecosystem.

To learn more about creating an Innovation Hub at RESI JPM 2027, contact Life Science Nation at salescore@lifesciencenation.com.

Gearing Up for RESI Boston: Master Your Fundraising & Development Strategy at the Pre-RESI Biotech Forum

July 28, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

On Monday, September 21, 2026, the day before RESI Boston 2026, Life Science Nation (LSN) and RESI Boston Silver Sponsor, Certara, will host a Biotech Forum focused on Developing Investor Ready Strategies.

Designed for early-stage biotech companies, the workshop will help founders evaluate their company’s readiness for a global fundraising campaign by identifying opportunities to strengthen their development strategy and reduce key scientific, clinical, regulatory, commercial, and fundraising risks. Through expert-led sessions and interactive discussions, attendees will gain practical insights into what investors look for during diligence, how to build a credible development roadmap, and how to position their company for successful fundraising.

Held immediately before RESI Boston, the workshop gives companies the opportunity to refine their strategy and messaging before meeting with investors and strategic partners throughout RESI.

Not yet signed up for RESI Boston 2026: Register Here

We look forward to welcoming you to the CIC in Cambridge as we kick off RESI Boston 2026 with a day dedicated to helping innovative biotech companies become truly investor ready.

Finding the Right Investors Starts with the Right Data

July 21, 2026July 21, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

For early-stage life science companies, fundraising success depends on connecting with investors who are actively looking for technologies like yours. That is why Life Science Nation (LSN) has spent years building one of the industry’s most comprehensive investor databases, designed specifically to help innovators identify the right capital partners.

Unlike generic databases built through web scraping, the LSN Investor Database is curated directly through 1:1 interviews with investors and strategic in-licensors, providing startups with insights that go far beyond basic contact information or what you find on an investor’s website. Each investor profile includes valuable details such as typical check size, preferred modalities and indications, stage of development, geographic focus, and more, allowing companies to build a highly targeted fundraising strategy.

The database includes more than 4,000 global investment firms across 10 distinct investor categories and over 12,000 investor contacts spanning therapeutics, medical devices, diagnostics, digital health, and other life science sectors. Whether you are raising a Seed, Series A, or Series B round, identifying investors who are an actual fit can save significant time and improve the quality of your outreach.

Not sure where to begin? Life Science Nation is offering a complimentary investor search to help companies uncover potential investors that may not already be on their radar. The search demonstrates how the LSN Investor Database can provide each company with a curated list of investors matched to their technology and stage of development, along with contact information to then go out and execute on a fundraising campaign.

LSN is also happy to offer a free Fundraising Readiness Assessment through our internally developed AI Agent. The assessment will generate a 6-page report that can be used to help transition your companies’ story from an “interesting technology” into a compelling and ultimately investable company.

Book your free investor search today or complete the AI assessment to take the first step toward building a more focused and effective fundraising campaign.

Book Your Free Investor Search Today

RESI Boston 2026 Agenda Announced: Two Days of Investor Insights, Partnership Strategy, and Networking

July 14, 2026July 14, 2026 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The agenda for RESI Boston 2026 is here, offering attendees an in-depth look at the conversations shaping the future of early-stage life science investment. Taking place September 22–23 at The Westin Copley Place in Boston, followed by virtual partnering days on September 25, 28, and 29, the expanded two-day in-person conference delivers more opportunities than ever to connect with investors, strategic partners, and industry leaders.

This year’s program reflects the evolving priorities of the healthcare investment ecosystem, with sessions designed to help innovators better understand today’s fundraising environment while building the relationships needed to move their companies forward.

Day one begins by exploring why Boston remains one of the world’s premier biotechnology hubs before examining key topics including partnering with health systems, how venture investors evaluate early-stage therapeutics, securing pharmaceutical partnerships, corporate venture capital strategies, digital health innovation, and the growing influence of family offices in healthcare investing. The day also features the Global Family Office Bioforum (GFOB), an invite-only private networking lunch that brings together select family office investors for high-value discussions and relationship building.

On day two, programming shifts toward emerging investment trends with sessions highlighting angel investing, women’s health, impact investing, and the increasingly important role of mission-driven capital. The conference concludes with two Reverse VC Pitch sessions, where investors take the stage to present directly to entrepreneurs, providing attendees with valuable insight into investment priorities, fund strategies, and what investors are actively seeking in new opportunities. The day also features the exclusive Global VC Connect Lunch, creating another dedicated opportunity for venture capital investors to build meaningful connections.

As always, RESI programming is designed to provide practical insights rather than theory. Whether attendees are preparing for their next fundraising round, pursuing strategic partnerships, or looking to better understand today’s investment landscape, every panel is curated to deliver actionable perspectives from experienced investors and industry leaders.

Combined with RESI’s partnering platform and three additional days of virtual meetings, the conference offers a comprehensive environment for companies seeking to advance fundraising and business development efforts.

Join the RESI Speaker Lineup

Are you an investor or strategic partner with valuable insights to share with early-stage life science companies? We are looking for dynamic speakers to join our RESI panels. Click here to submit your Speaker Interest Form today!

Registration is now open, with super early bird pricing currently available. Companies planning to attend are encouraged to register early to secure the best available rates and begin preparing for one of the most anticipated life science investment events of the year.

Registration Now Open for RESI JPM 2027

July 7, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

Life Science Nation is excited to announce that registration is now open for RESI JPM 2027, taking place January 11–12 at the San Francisco Marriott Marquis, followed by three days of virtual partnering on January 13, 18, and 19.

Held alongside the world’s largest gathering of healthcare investors, executives, and innovators during JPM Week, RESI JPM provides early-stage life science companies with a unique opportunity to raise capital, build strategic partnerships, and accelerate business development in one of the industry’s most active networking environments.

Previous RESI JPM conferences welcomed more than 1,000 attendees, including over 600 active investors, strategic partners, pharmaceutical business development professionals, and industry leaders. The conference combines curated educational programming with one-on-one partnering meetings, creating meaningful opportunities for fundraising companies to connect directly with the investors and partners best aligned with their technologies.

The expanded format begins with two full days of in-person programming at the San Francisco Marriott Marquis, featuring investor panels, educational workshops, the Innovator’s Pitch Challenge, networking events, poster presentations, and partnering meetings. The conference then continues online with three additional days of virtual partnering, allowing participants to maximize the number of meetings they can schedule while extending networking opportunities beyond the in-person event.

Whether you are seeking Seed, Series A, or Series B financing, exploring strategic partnerships, licensing opportunities, or looking to expand your visibility within the life science investment community, RESI JPM offers multiple ways to engage. Registration options are available for startups, fundraising executives, service providers, technology hubs, exhibitors, and qualified investors.

Early Bird registration is now available, offering substantial savings on five-day hybrid registration for startups and fundraising executives. Register early to lock in the lowest available rates.

Organizations looking to maximize their visibility during JPM Week can also take advantage of sponsorship and exhibition opportunities designed to connect brands with a highly targeted audience of investors, innovators, and industry leaders.

Register today and save up to $900 with Super Early Bird pricing!

Register Now

Don’t miss your opportunity to be part of one of the life science industry’s premier fundraising and partnering events.

RESI San Diego Innovator’s Pitch Challenge Winners Showcase the Future of Life Science Innovation

June 30, 2026June 30, 2026 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Innovator’s Pitch Challenge (IPC) returned to RESI San Diego 2026, bringing together some of the most promising early-stage life science companies for one of the conference’s signature events. Designed to connect early-stage innovators with active investors and strategic partners, the IPC provides a platform for companies to showcase breakthrough technologies while gaining valuable exposure and feedback.

Each finalist delivered a six-minute presentation followed by a live Q&A with an investor judging panel. Throughout the conference, participants also met with investors during one-on-one partnering meetings and networking sessions, extending conversations well beyond the pitch stage.

The IPC winners are determined through a combination of investor judge evaluations and RESI Cash voting. Judges evaluate each company based on the strength of its technology, investment opportunity, presentation, and responses during Q&A, while attendees allocate RESI Cash to the companies they believe demonstrate the greatest investment potential. Together, these scores recognize companies that impressed both the judging panel and the broader RESI community.

Congratulations to the overall winners of the RESI San Diego 2026 Innovator’s Pitch Challenge:

1st Place: Nanotrace

Nanotrace combined the best attributes of chemotherapy, nanoparticle delivery mechanisms, and the latest advancements in gene therapeutics to build a revolutionary oncology platform. Based on our team’s decades of research in these fields, and the maturation of nanomedicine, our product is a novel targeting platform which recognizes cancer cells by its very blueprint – gene expression. In part by using AI, that highly specific recognition is programmed to release a chemotherapeutic payload inside a cancer cell while leaving healthy cells unaffected. Our platform will transform how we treat not only cancer but a whole spectrum of genetic disorders. Nanotrace is founded by Dr. Will Briley, PhD Molecular Biology from Northwestern; Dr. Paul Weiss, renowned nanoscientist, distinguished UCLA professor, and a UC Presidential Chair; David Spector, an experienced founder and formerly of Sequoia Capital, Google, and MIT; and, Chief Medical Advisor, Dr. Krishna Komanduri, Department Chief & Head of Hematology & Oncology, UCSF.

2nd Place: Pinion Immunotherapeutics

Pinion Immunotherapeutics is a Maryland-based biotechnology company focused on developing novel immunotherapies for chronic viral infections and virus-driven cancers. Its proprietary AI-driven mRNA platform generates immunotherapies targeting HPV-related precancer, AML, EBV, and HSV, designed to activate CD8⁺ T cells while inducing virus-neutralizing antibodies to achieve durable immune control. Pinion operates as a lean, high-impact virtual company, deploying capital directly to science and clinical trials, not overhead. Our leadership team brings deep expertise across mRNA platform development, FDA regulatory strategy, clinical trial design, and immunology. Our programs target indications with large addressable populations, no curative standard of care, and high economic burden, where mRNA immunotherapy offers a genuine path to functional cure.

3rd Place: FELIQS

Feliqs is a clinical-stage ophthalmology company developing innovative therapies for retinal and corneal diseases with significant unmet medical needs. The company is advancing a diversified pipeline targeting conditions including retinopathy of prematurity (ROP), pterygium, and dry age-related macular degeneration (Dry AMD), addressing diseases that currently have limited or no effective treatment options. Leveraging novel mechanisms targeting oxidative stress, fibrosis, and angiogenesis, FELIQS is developing patient-friendly therapies designed to reduce dependence on invasive procedures while improving long-term visual outcomes. Through its innovative ophthalmology pipeline, FELIQS aims to preserve vision, prevent blindness, and improve quality of life for patients worldwide.

In addition to the overall winners, several companies earned the highest combined judge and RESI Cash scores within their individual pitch sessions. Congratulations to these outstanding innovators for delivering exceptional presentations and capturing investor interest throughout the competition.

Every company that participated in the Innovator’s Pitch Challenge demonstrated the innovation, passion, and entrepreneurial spirit that continue to define the RESI community. Congratulations to all of this year’s participants.

Will Your Company Be Next?

Applications are now open for the RESI Boston Innovator’s Pitch Challenge, taking place during the expanded two-day, in-person RESI Boston conference this September during Biotech Week Boston.

The IPC is more than a pitch competition. It is an opportunity to present your company to active investors, receive expert feedback, gain additional visibility through poster presentations and partnering meetings, and compete for recognition among the global life science investment community.

Whether you’re preparing for your next financing round or looking to build strategic partnerships, the Innovator’s Pitch Challenge can help elevate your fundraising efforts.

Applications are now open. Apply today and take the stage at RESI Boston.

Apply to Pitch at RESI Boston

Build Your Brand at the Expanded Two-Day RESI Boston

June 30, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

Following the success of RESI San Diego, sponsorship opportunities are now available for RESI Boston, taking place September 22–23 during Biotech Week Boston. With two days of in-person programming, followed by three days of virtual partnering, RESI Boston offers even more opportunities to connect with the global life science investment community.

RESI San Diego welcomed an outstanding group of sponsors representing every corner of the life science ecosystem. Title Sponsors included Innopolis Jeonbuk Innovation Cluster, Biometas, and Korea Bio Innovation Center (KBIC). Gold Sponsors RSM and Medmarc shared their expertise through thought leadership and networking, while Silver Sponsors Biocytogen, Foley Hoag, and Polsinelli connected with innovators and investors throughout the conference. Additional support from Bronze Sponsors BSR Korea, JABI, Jeongup Si, Jeonbuk State, the Ministry of Science and ICT (Korea), Alithia Life Sciences, and Inertia further strengthened the event’s international reach.

Sponsoring RESI is more than displaying your logo. Sponsors gain visibility before, during, and after the conference through digital marketing, onsite branding, exhibit opportunities, educational programming, and access to RESI’s partnering platform. Whether your organization is looking to generate business leads, recruit new clients, showcase a regional innovation ecosystem, or establish thought leadership, RESI provides direct access to founders, investors, strategic partners, and service providers actively shaping the future of life sciences.

The expanded two-day in-person format at RESI Boston means more networking, more meetings, more educational sessions, and more opportunities for meaningful engagement than ever before. Combined with virtual partnering that continues after the event, sponsors benefit from sustained visibility and valuable follow-up opportunities well beyond the conference itself.

Ready to elevate your brand at RESI Boston? Explore the full range of sponsorship opportunities by downloading the RESI Sponsorship Brochure, or visit the RESI Sponsors page to learn more. To discuss a customized sponsorship package that aligns with your business development goals, contact sales@lifesciencenation.com. Sponsorship packages can be tailored to maximize your visibility, thought leadership, and connections within the global life science investment community.